Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

Filings

Form TypeForm DescriptionFiling DateReport DateView Report
S-1General form for registration of securities under the Securities Act of 193312/7/2022
DNotice of Exempt Offering of Securities12/6/2022
3Initial statement of beneficial ownership of securities11/29/202211/16/2022
8-KCurrent report11/22/202211/21/2022
4/AStatement of changes in beneficial ownership of securities - amendment11/18/202211/14/2022
4/AStatement of changes in beneficial ownership of securities - amendment11/18/202211/14/2022
4/AStatement of changes in beneficial ownership of securities - amendment11/18/202211/14/2022
4/AStatement of changes in beneficial ownership of securities - amendment11/18/202211/14/2022
4/AStatement of changes in beneficial ownership of securities - amendment11/18/202211/14/2022
8-KCurrent report11/17/202211/17/2022
8-KCurrent report11/17/202211/16/2022
4Statement of changes in beneficial ownership of securities11/15/202211/14/2022
4Statement of changes in beneficial ownership of securities11/15/202211/14/2022
8-KCurrent report11/15/202211/11/2022
4Statement of changes in beneficial ownership of securities11/15/202211/14/2022
4Statement of changes in beneficial ownership of securities11/15/202211/14/2022
4Statement of changes in beneficial ownership of securities11/15/202211/14/2022
10-QQuarterly report [Sections 13 or 15(d)]11/14/20229/30/2022
S-8Securities to be offered to employees in employee benefit plans11/14/2022
DEF 14AOther definitive proxy statements10/28/202212/15/2022
DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material10/28/2022
8-KCurrent report10/26/202210/26/2022
424B3Prospectus [Rule 424(b)(3)]10/19/2022
EFFECTNotice of Effectiveness10/18/2022
UPLOADSEC-generated letter10/14/2022
CORRESPCorrespondence10/14/2022
S-1General form for registration of securities under the Securities Act of 193310/12/2022
EFFECTNotice of Effectiveness10/7/2022
EFFECTNotice of Effectiveness10/7/2022
EFFECTNotice of Effectiveness10/7/2022
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next »

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent